Stock Price Prediction

ALVO stock is currently trading at $12.46, near its 52-week low of $10.50, indicating potential undervaluation. The FDA's acceptance of the Biologics License Application for AVT05, a biosimilar to Simponi, positions Alvotech for significant growth if approval is granted by Q4 2025. However, the stock recently broke below its 200-day moving average, signaling bearish technical momentum in the short term.

ALVO stock is bearish, trading at $12.46, near its 52-week low of $10.50, and recently broke below its 200-day moving average, signaling weak technical momentum. The FDA review of its biosimilar AVT05, expected by Q4 2025, offers long-term potential but has no immediate impact on valuation. Current price action suggests further downside risk in the short term.

The market consensus for ALVO's eps in the upcoming quarter is projected to be approximately $0.018 USD.